ReviewSignal transduction and targeted therapy2023
Applications of synthetic biology in medical and pharmaceutical fields.
Review in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 139 citations in OpenAlex.
- Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective.Synthetic and systems biotechnology · 2026Review
- BiohybridMaterials today. Bio · 2026Article
- Rheological Characterization of Yeast Protein-Sanxan Composite Hydrogels via SAOS, LAOS and Thermal Analysis.Gels (Basel, Switzerland) · 2026Article
- A Programmable DNA Biohybrid Material Coupled with Intelligent Cell-Free Computation for Environmental Sensing.ACS omega · 2026Article
- Accelerating the clinical translation of bioengineered anticancer therapeutics.Journal of the National Cancer Center · 2026Article
- Mathematical and Computational Models of Biochemical Reactions and Cell Signaling-From Ordinary Differential Equations to Machine Learning.International journal of molecular sciences · 2026Review
- Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Quantifying protein residues in APIs: Bradford assay mechanism and limitations, outperformed by HILIC-MS/MS.Journal of pharmaceutical analysis · 2026Article
- Evaluating DNA Function Understanding in Genomic Language Models Using Evolutionarily Implausible Sequences.ACS synthetic biology · 2026Article
- Tools For Building Artificial Biological Nanostructures.ACS nano · 2026Review
- Functions and optimization of soft law in the international governance of synthetic biology: The predicament of hard law vs. the rise of soft law.Synthetic and systems biotechnology · 2026Article
- A growth-coupled progesterone-responsive biosensor for high-throughput microfluidic screening inSynthetic and systems biotechnology · 2026Article
- Review
- Bioengineered Silver Nanoparticles: Next-Generation Biogenic Synthesis Strategies for Precision Biomedical Applications.Bioengineering (Basel, Switzerland) · 2026Review
- Synthetic control of implanted engineered liver tissue growth.Science advances · 2026Article
- Advancements in CRISPR-Cas Systems for Genome Editing towards Eradication of Human Microbial Pathogens.Molecular biotechnology · 2026Review
- Effects of microparticle composition on colony morphology and viability of encapsulated therapeutic yeast for oral delivery.RSC pharmaceutics · 2026Article
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- SUPER: Upcycling Genetic Parts for Precise Gene Expression Control, Leakage Minimization, and Genetic Circuit Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Synthetic Cell-Based Tissues for Bottom-Up Assembly of Artificial Lymphatic Organs.Advanced healthcare materials · 2026Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic biology aims to design or assemble existing bioparts or bio-components for useful bioproperties. During the past decades, progresses have been made to build delicate biocircuits, standardized biological building blocks and to develop various genomic/metabolic engineering tools and approaches. Medical and pharmaceutical demands have also pushed the development of synthetic biology, including integration of heterologous pathways into designer cells to efficiently produce medical agents, enhanced yields of natural products in cell growth media to equal or higher than that of the extracts from plants or fungi, constructions of novel genetic circuits for tumor targeting, controllable releases of therapeutic agents in response to specific biomarkers to fight diseases such as diabetes and cancers. Besides, new strategies are developed to treat complex immune diseases, infectious diseases and metabolic disorders that are hard to cure via traditional approaches. In general, synthetic biology brings new capabilities to medical and pharmaceutical researches. This review summarizes the timeline of synthetic biology developments, the past and present of synthetic biology for microbial productions of pharmaceutics, engineered cells equipped with synthetic DNA circuits for diagnosis and therapies, live and auto-assemblied biomaterials for medical treatments, cell-free synthetic biology in medical and pharmaceutical fields, and DNA engineering approaches with potentials for biomedical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.